{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T19:40:09Z","timestamp":1749325209257,"version":"3.41.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Breast cancer remains the most commonly diagnosed cancer among women. Imaging abnormalities may be noted on routine breast cancer screenings and require biopsy for further evaluation. Atypia and carcinoma in situ are nonmalignant lesions identified via breast biopsy and are associated with an increased risk of invasive carcinoma. Because of the lack of specialized breast cancer prevention and risk reduction programs, patients may not be able to access optimal management of the various subtypes of atypia and carcinoma in situ. By understanding the pathology of high-risk breast lesions and the resulting elevated cancer risk, healthcare providers, specifically primary care providers, can better counsel, manage, and treat patients to provide comprehensive quality care.<\/jats:p>","DOI":"10.1097\/01.jaa.0000742948.34484.aa","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T03:47:20Z","timestamp":1618890440000},"page":"35-39","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Managing patients with high-risk breast lesions, precursors on the breast neoplasia pathway"],"prefix":"10.1097","volume":"34","author":[{"given":"Katherine B.","family":"D'Antonio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meaghan","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karlyn","family":"Rupert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"2","key":"R2-20250607","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2214\/AJR.19.21991","article-title":"Atypical ductal hyperplasia and lobular neoplasia: update and easing of guidelines","volume":"214","author":"Lewin","year":"2020","journal-title":"Am J Roentgenol"},{"issue":"1","key":"R3-20250607","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJMsr1407164","article-title":"Atypical hyperplasia of the breast\u2014risk assessment and management options","volume":"372","author":"Hartmann","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"R4-20250607","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-018-05071-1","article-title":"Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)","volume":"174","author":"Rageth","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"R5-20250607","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/cncr.29243","article-title":"Flat epithelial atypia and risk of breast cancer: a Mayo cohort study","volume":"121","author":"Said","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"R6-20250607","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1245\/s10434-017-5978-0","article-title":"Lobular neoplasia and atypical ductal hyperplasia on core biopsy: current surgical management recommendations","volume":"24","author":"Racz","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"R7-20250607","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.clbc.2014.12.005","article-title":"Magnetic resonance imaging-guided core needle breast biopsies resulting in high-risk histopathologic findings: upstage frequency and lesion characteristics","volume":"15","author":"Weinfurtner","year":"2015","journal-title":"Clin Breast Cancer"},{"issue":"10","key":"R9-20250607","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1245\/s10434-018-6591-6","article-title":"Treatment Outcomes for pleomorphic lobular carcinoma in situ of the breast","volume":"25","author":"Desai","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"R10-20250607","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejso.2019.10.029","article-title":"Pure flat epithelial atypia identified on core needle biopsy does not require excision","volume":"46","author":"Liu","year":"2020","journal-title":"Eur J Surg Oncol"},{"issue":"1081","key":"R11-20250607","doi-asserted-by":"crossref","first-page":"20170484","DOI":"10.1259\/bjr.20170484","article-title":"Flat epithelial atypia: conservative management of patients without residual microcalcifications post-vacuum-assisted breast biopsy","volume":"91","author":"Schiaffino","year":"2018","journal-title":"Br J Radiol"},{"issue":"33","key":"R12-20250607","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.19.01472","article-title":"Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update","volume":"37","author":"Visvanathan","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"R14-20250607","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jso.25611","article-title":"Screening of populations at high risk for breast cancer","volume":"120","author":"Lee","year":"2019","journal-title":"J Surg Oncol"},{"issue":"9","key":"R15-20250607","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/jama.2019.11885","article-title":"Medication use to reduce risk of breast cancer: US Preventive Services Task Force recommendation statement","volume":"322","author":"Owens","year":"2019","journal-title":"JAMA"},{"issue":"1","key":"R16-20250607","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1586\/14737140.9.1.51","article-title":"The NSABP Study of Tamoxifen and Raloxifene (STAR) trial","volume":"9","author":"Vogel","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"issue":"19","key":"R17-20250607","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1200\/JCO.18.01779","article-title":"Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia","volume":"37","author":"DeCensi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"25","key":"R18-20250607","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","article-title":"Exemestane for breast-cancer prevention in postmenopausal women","volume":"364","author":"Goss","year":"2011","journal-title":"N Engl J Med"},{"issue":"10218","key":"R19-20250607","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(19)32955-1","article-title":"Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial","volume":"395","author":"Cuzick","year":"2020","journal-title":"Lancet"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000742948.34484.aa","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T19:01:25Z","timestamp":1749322885000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000742948.34484.aa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000742948.34484.aa","relation":{},"ISSN":["1547-1896"],"issn-type":[{"type":"print","value":"1547-1896"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}